Lack of Interaction of Gabapentin with Carbamazepine or Valproate |
| |
| Authors: | Louis L Radulovic B J Wilder Ilo E Leppik† Howard N Bockbrader Tsun Chang Edward L Posvar Allen J Sedman Basim M Uthman Gary R Erdman† |
| |
| Institution: | Departments of PharmacokineticslDrug Metabolism and Clinical Pharmacology, Parke-Davis Pharmaceutical Research, Division of Warner-Lumhert Company, Ann Arbor, Michigan, U.S.A.;V.A. Medical Center Hospital, Gainesville, Florida, U.S.A.;College of Pharmacy and MINCEP Epilepsy Cure P.A., University of Minnesota, Minneapolis, Minnesota, U.S.A. |
| |
| Abstract: | Summary: Gabapentin (GBP) studies were conducted in patients with epilepsy receiving carbamazepine (CBZ, n= 12) or valproate (VPA, n = 14) monotherapy. The effects of GBP coadministration on steady-state CBZ or VPA concentrations and of these antiepileptic drugs (AEDs) on GBP pharmacokinetics were investigated. GBP (400 mg) was coadministered every 8 h for 3% days with CBZ or for 5 1/3 days with VPA. GBP was well tolerated. Mean steady-state plasma CBZ/CBZ-10, ll-epoxide (CBZ-E) and serum VPA concentrations before, during, and after GBP administration were not significantly different. Mean steady-state GBP pharmacokinetic parameters during CBZ or VPA coadministration were similar to steady-state parameters reported in healthy subjects. Thus, no pharmacokinetic interaction exists between CBZ or VPA and GBP. No dosage adjustment is necessary when GBP and CBZ or VPA are coadministered. |
| |
| Keywords: | Anticonvulsants Gabapentin Pharmacokinetics Drug interaction-carbamazepine Valproate-Drug toxicity |
|
|
